Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialHertzel C. Gerstein, Anselmo P. Bordonava, Rafael Díaz et al.|The Lancet|2019Cited by 3.1k
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trialHertzel C. Gerstein, Anselmo P. Bordonava, Helen M. Colhoun et al.|The Lancet|2019Cited by 640
Optimization of Therapy in Patients with Epilepsy and Psychiatric Comorbidities: Key PointsFrancesco Pisani, Edoardo Spina, Laura Rosa Pisani et al.|Current Neuropharmacology|2022Cited by 26